IMO, and shooting high here, I would like to see at least 4 mil/ QTR through Q3, because we know we had trouble advertising in Q4 last year, due to the heavy weights eating up ad space. But I dont think a Q1 of 2.2-2.3 is necessarily a negative considering thats nearly half of what they did in all of 2016, but I would like to see better numbers. Q2 is the most important for me, to see if we will be on track for 15mil w/o Fluticare.
- If approval doesn't come by the end of Q2, im not worried at all, the FDA has up until the end of November 2017 to provide us a resolution on Fluticare. I wasn't happy about Dr. D changing the terms of of the original agreement with Novalere, and gifting them the remaining shares without approval, regardless of any restrictions from selling the shares up to a specific date. I wouldn't have made that call personally, but Dr. D has WAY more information than us, so I am still confident in his leadership at this time.
- I agree, but i'm guessing Q4 comes in at about 2.5-3 mil. Time will tell.
- As an investor, one should do their own DD before investing, and I for one never listen to anyone on a message board to determine what I invest in, and what my investment strategy will be. 9 months ago if you weren't invested, you definitely missed the boat up until the end of August. so its easy to say now you havent missed the boat to make some cash. We are a small microcap, right now we are down, next month could be a different story.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.